JP2019112416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112416A5
JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
exemestane
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026073A
Other languages
English (en)
Japanese (ja)
Other versions
JP6860949B2 (ja
JP2019112416A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112416A publication Critical patent/JP2019112416A/ja
Publication of JP2019112416A5 publication Critical patent/JP2019112416A5/ja
Application granted granted Critical
Publication of JP6860949B2 publication Critical patent/JP6860949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026073A 2013-05-03 2019-02-15 癌の処置方法 Active JP6860949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016512076A Division JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Publications (3)

Publication Number Publication Date
JP2019112416A JP2019112416A (ja) 2019-07-11
JP2019112416A5 true JP2019112416A5 (https=) 2019-09-19
JP6860949B2 JP6860949B2 (ja) 2021-04-21

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (https=)
JP (2) JP2016522188A (https=)
KR (1) KR102337598B1 (https=)
CN (1) CN105492007A (https=)
HK (1) HK1223547A1 (https=)
WO (1) WO2014179738A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990687A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
CN111278459A (zh) * 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
WO2009109844A1 (en) * 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
MX358254B (es) * 2011-09-02 2018-08-10 Syndax Pharmaceuticals Inc Métodos para el tratamiento de cáncer de mama.

Similar Documents

Publication Publication Date Title
JP2019112416A5 (https=)
US9763898B2 (en) Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
JP2019048843A5 (https=)
JP2022121594A5 (https=)
RU2022102537A (ru) Нейроактивные стероиды, их композиции и применения
JP2023107883A5 (https=)
JP2014528901A5 (https=)
JP2022552187A5 (https=)
JP2023153863A (ja) 15-hepeを含む組成物及びその使用方法
JP2015503593A5 (https=)
JP2014525465A5 (https=)
JP2013529665A5 (https=)
JP2020532531A5 (https=)
JP2016522188A5 (https=)
Mantovani Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2017514858A5 (https=)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2024529430A5 (https=)
JP2023531930A5 (https=)
JP2019535830A5 (https=)
Jagmeet et al. Kanchnar Guggulu and Varunadi Kashaya in Hypothyroidism-A Case Study
Teng et al. Neuroprotection of maslinic acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats
JP2016514142A5 (https=)
JP2015231976A (ja) 心筋炎の予防または治療剤